Antiviral drug for post-transplant complications now costs more than the transplant
June 2, 2016
| By Mary Engel / Fred Hutch News Service
A life-saving antiviral drug used to treat a type of severe pneumonia in children and adults who have undergone bone marrow transplants can now cost more than the transplant itself after the drug’s sole distributor, Valeant Pharmaceuticals, increased the price by almost 400 percent.
Guang-Shing Cheng helps immunocompromised patients with respiratory illnesses, aims to detect lung cancer earlier
April 30, 2012
| By Colleen Steelquist
Dr. Guang-Shing Cheng has joined the Fred Hutchinson Cancer Research Center's Clinical Research Division faculty. Her research focuses on improving outcomes for stem cell transplant patients with respiratory failure and on advancing diagnostic strategies for early detection of lung infections and cancer.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.